Enanta Pharmaceuticals (ENTA) Receives a Buy from Robert W. Baird

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Enanta Pharmaceuticals (ENTAResearch Report) on February 9 and set a price target of $130.00. The company’s shares closed last Friday at $64.14.

According to TipRanks.com, Skorney is ranked 0 out of 5 stars with an average return of -5.1% and a 43.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Reata Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $87.67 average price target, which is a 35.5% upside from current levels. In a report issued on February 9, JMP Securities also reiterated a Buy rating on the stock with a $116.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Enanta Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $27.65 million and GAAP net loss of $30.12 million. In comparison, last year the company earned revenue of $31.74 million and had a GAAP net loss of $8.33 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Jay Luly, the President & CEO of ENTA bought 10,063 shares for a total of $118,442.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Read More on ENTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed